The University of Central Lancashire (UCLan) and Brinton Healthcare UK Ltd. have embarked on a significant collaborative research endeavor aimed at revolutionizing the treatment of skin diseases through the application of cutting-edge nanotechnology. By entering into a Memorandum of Understanding (MoU), both institutions have committed to leveraging their unique strengths to develop innovative skincare and dermatological therapies utilizing advanced nanoparticle technology. Spearheading this innovative research initiative is Professor Kamalinder Singh from UCLan, whose primary focus will be on creating topical nanocarriers for more effective and targeted treatment.
Nanotechnology offers a groundbreaking approach to delivering drugs with much greater precision, using nanoparticles that are far smaller than the thickness of a human hair. This advanced method ensures controlled and sustained release, deep penetration into the skin, and a reduction in side effects typically associated with conventional treatments. The research aims to discover new solutions for chronic skin conditions such as psoriasis and atopic dermatitis. Alongside the health benefits, the collaboration holds the potential to generate valuable intellectual property and commercial opportunities, paving the way for pioneering skincare products to enter the market.
Vision and Goals
Rahulkumar Darda, Chairman and Managing Director of Brinton Pharmaceuticals Ltd., emphasized the company’s unwavering dedication to creating pioneering skincare solutions that are accessible to a broad audience. Professor Singh also highlighted the benefits of using topical nanocarriers, including improved stability and lower toxicity compared to traditional treatments. Their combined expertise sets the stage for developing revolutionary products that cater to various consumer needs.
According to Dr. Praveen Kumar Tavva, Director and Chief Scientific Officer at Brinton, the collaboration is a cornerstone for expanding the company’s research and development operations in the United Kingdom. The goal is to tailor products to meet the diverse skincare needs of consumers, leveraging the academic and clinical insights from UCLan. Vijey Christopher, Head of International Business at Brinton, further noted that the strategic partnership plays a pivotal role in advancing groundbreaking skincare technologies. The synergy between Brinton’s pharmaceutical expertise and UCLan’s academic prowess is expected to yield substantial advancements in skin health and overall well-being.
Formalization and Future Impact
The University of Central Lancashire (UCLan) and Brinton Healthcare UK Ltd. have launched a collaborative research initiative targeting advancements in skin disease treatments using groundbreaking nanotechnology. By signing a Memorandum of Understanding (MoU), both organizations are uniting their unique capabilities to create cutting-edge skincare and dermatological therapies through advanced nanoparticle technology. Leading this innovative research is Professor Kamalinder Singh from UCLan, who will focus on developing topical nanocarriers for more precise and efficient treatment.
Nanotechnology presents a revolutionary method for drug delivery, involving nanoparticles much finer than a human hair’s thickness. This technique allows for controlled, sustained release, deep skin penetration, and a reduced incidence of side effects compared to traditional treatments. The primary objective of the research is to address chronic skin conditions like psoriasis and atopic dermatitis. Beyond health benefits, this collaboration could also result in valuable intellectual property and commercial prospects, setting the stage for groundbreaking skincare products to reach the market.
